Search results
Results from the WOW.Com Content Network
Cancer cells can also cause defects in the cellular pathways of apoptosis (programmed cell death). As most chemotherapy drugs kill cancer cells in this manner, defective apoptosis allows survival of these cells, making them resistant. Many chemotherapy drugs also cause DNA damage, which can be repaired by enzymes in the cell that carry out DNA ...
Chemotherapy can boost tumor immunity in two main ways: (a) by killing cancer cells through immunogenic cell death, and (b) by affecting both cancerous and normal cells in the tumor environment. Despite this, many chemotherapy treatments can also suppress the immune system by causing lymphopenia or impairing lymphocyte function.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Immunosuppressive drugs can be used to control the immune system with organ transplantation and with autoimmune disease. Immune responses depend on lymphocyte proliferation. Lymphocyte proliferation is the multiplication of lymphocyte cells used to fight and remember foreign invaders. [60]
These cells usually repair themselves after chemotherapy. Because some drugs work better together than alone, two or more drugs are often given at the same time. This is called "combination chemotherapy"; most chemotherapy regimens are given in a combination. [12] Since chemotherapy affects the whole body, it can have a wide range of side effects.
For premium support please call: 800-290-4726 more ways to reach us
Chemotherapy will be the standard treatment for many of those patients. Chemotherapy drugs work by killing cancer cells. While often effective, they can also come with major side effects because ...
Crohn's disease, rheumatoid arthritis, ankylosing spondylitis: Respiratory infection, fever, hypotension. Predisposes to infections (reactivation of latent TB) Rituximab (Rituxan) A monoclonal antibody to CD20 surface immunoglobulin Lymphoma and a variety of autoimmune diseases, although it may be ineffective in treating IgA-mediated diseases. [13]